Risk management - A European regulatory perspective

被引：7
|
作者：
Moseley, JNS [1 ]
机构：
[1] Med & Healthcare Prod Regulatory Agcy, Pharmacoepidemiol Res Team, London SW8 5NQ, England
来源：
DRUG SAFETY | 2004年 / 27卷 / 08期
关键词：
European Union; Medicinal Product; Marketing Authorisation; Orphan Medicinal Product; Marketing Authorisation Application;
D O I：
10.2165/00002018-200427080-00003
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Risk management for European regulators means the detection and assessment of risks, the development and selection of measures to reduce risk, and monitoring of the effectiveness of risk control; all aspects of pharmacovigilance intended to minimise risk to European Union citizens associated with use of medicinal substances. This incorporates earlier and better planning of pharmacovigilance through formal product risk-management plans, better use of information tools to protect public health and routine audit of effectiveness of regulatory action.
引用
收藏
页码：499 / 508
页数：10
相关论文
共 50 条
  • [1] A Swedish regulatory perspective on European risk management
    Hedenmalm K.
    Alvan G.
    [J]. International Journal of Pharmaceutical Medicine, 2007, 21 (2) : 131 - 145
  • [2] Risk ManagementA European Regulatory Perspective
    Jane N. S. Moseley
    [J]. Drug Safety, 2004, 27 : 499 - 508
  • [3] Resistance risk evaluation, "a European regulatory perspective"
    Leonard, PK
    [J]. CROP PROTECTION, 2000, 19 (8-10) : 905 - 909
  • [4] REGULATORY ISSUES IN RISK MANAGEMENT - A CALIFORNIA PERSPECTIVE
    LERCARI, FA
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1991, 202 : 21 - CHAS
  • [5] Guidelines and management of global risk: the European perspective
    Hobbs, FDR
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2004, 6 (0C) : C5 - C14
  • [6] European Perspective on Risk Management and Drug Safety
    Raine, J.
    Wise, L.
    Blackburn, S.
    Eichler, H-G
    Breckenridge, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 650 - 654
  • [7] Documenting High-Risk AI: A European Regulatory Perspective
    Hupont, Isabelle
    Micheli, Marina
    Delipetrev, Blagoj
    Gomez, Emilia
    Garrido, Josep Soler
    [J]. COMPUTER, 2023, 56 (05) : 18 - 27
  • [8] Rosiglitazone: a European regulatory perspective
    Blind, E.
    Dunder, K.
    de Graeff, P. A.
    Abadie, E.
    [J]. DIABETOLOGIA, 2011, 54 (02) : 213 - 218
  • [9] Rosiglitazone: a European regulatory perspective
    E. Blind
    K. Dunder
    P. A. de Graeff
    E. Abadie
    [J]. Diabetologia, 2011, 54 : 213 - 218
  • [10] Risk management from an Asian/Pacific rim regulatory perspective
    McEwen, J
    [J]. DRUG SAFETY, 2004, 27 (08) : 491 - 497
12345